Some two novel urine tests have been developed that will improve the patients’ outcome for bladder cancer. These tests are significant upgrades of the existing urine tests for bladder cancer. The current urine tests have been inaccurate, invasive, and expensive.
Causes of bladder cancer
Bladder cancer has been causing high death rates as compared to other types of cancer. The many deaths are due to the difficulties and complications in detecting the cancer. Some tests from specific biomarkers have been used and have been giving high rates of false information. The usual methods that have been used over time have been cystoscopy. It involves inserting a camera into the urethra of a patient, which is unpleasant to a lot patients.
The latest urine tests can measure a gene variant called V1 that is elevated in the bladder of the patient who has bladder cancer. Furthermore, the gene extracts sections of the bladder wall, giving a chance for cancer tumors to grow there. It was discovered by Dr. Vinata Lokeshwar, one of the leading scientists at the Department of Molecular Biology and Biochemistry from Medical College of Georgia.
Detecting bladder cancer using the urine test
One of these tests works by measuring the levels of the enzymes that are created by V1. The second method works by measuring the amount of V1 in a patient’s system, depending on the mRNA excreted from urine. Both ways have an accuracy of about 90% in detecting bladder cancer.
These tests have proven to be more trustworthy when it involves high-grade tumors, boasting a 95% success rate in detecting bladder cancer. The piloting studies also gave a clear indication that the V1 test could have the capability of detecting the high-grade tumors. It could detect the tumors six months earlier than the invasive cystoscopy could do. These early detections could lead to increased survival among patients who have bladder cancer.
Using this simplified and accurate urine test for bladder cancer can also offer a patient ample recovery time and it helps in detecting any early forms of recurrence. However, these recurrences are always low in patients with low-grade bladder cancer. For patients with high-grade bladder cancer, their recurrence is always at 80% within three years, making it possible to detect it at the early stages. This is good news to patients who have bladder cancer as these two methods will be of great help to them in reducing mortality rates. Biomedical industry watchers say companies like DarioHealth Corp. (NASDAQ: DRIO) are also working to keep bringing better treatment options, so different patients can have hope that everything is being done to treat their ailments.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.